Skip to main content

Table 2 Adverse events

From: Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study

Organ system

Total

ATII

Placebo

P-value

Metabolic disorders

16

11

5

 

Acidosis

 

2

3

1.00

Alkalosis

 

4

0

0.09

Blood or lymphatic disorders

7

3

4

1.00

Respiratory disorders

6

3

3

1.00

Worsening respiratory failure

 

1

3

0.58

Wheezing

 

1

0

1.00

Cardiac disorders

12

7

5

0.65

Hypertension1

 

2

0

0.58

Hypotension

 

2

1

1.00

Atrial fibrillation

 

2

0

0.47

Renal disorders2

7

6

2

0.17

Decreased urine output

 

3

1

0.58

Worsening acute kidney injury

 

0

2

0.47

Other disorders3

8

5

3

0.65

Worsening multiple organ system failure

 

2

3

1.00

  1. The results were presented as number of adverse events. 1Angiotensin II (ATII) infusion was discontinued in two patients due to hypertension. 2Of 20 patients 17 exhibited pre-existing acute kidney injury (AKI), including 8 patients receiving placebo and 9 patients receiving ATII. Of the three patients who did not have pre-existing AKI, one patient developed AKI and received ATII. 3Includes worsening multiple organ system failure, fever, lower extremity edema, and thigh hematoma. P-values were calculated using the Fisher exact test.